[go: up one dir, main page]

MA41107B1 - Compositions anti-cancéreuses - Google Patents

Compositions anti-cancéreuses

Info

Publication number
MA41107B1
MA41107B1 MA41107A MA41107A MA41107B1 MA 41107 B1 MA41107 B1 MA 41107B1 MA 41107 A MA41107 A MA 41107A MA 41107 A MA41107 A MA 41107A MA 41107 B1 MA41107 B1 MA 41107B1
Authority
MA
Morocco
Prior art keywords
arn
prostate cancer
hpmcas
resistant prostate
solid dispersion
Prior art date
Application number
MA41107A
Other languages
English (en)
Other versions
MA41107A (fr
Inventor
Dennis Martin HESTER
Jason Michael VAUGHN
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41107(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of MA41107A publication Critical patent/MA41107A/fr
Publication of MA41107B1 publication Critical patent/MA41107B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques d'ARN-509, qui peuvent être administrées à un mammifère, en particulier un être humain, souffrant d'une maladie ou d'un état lié à un récepteur d'androgène (AR), en particulier un cancer, plus en particulier le cancer de la prostate y compris, mais sans s'y limiter, le cancer de la prostate résistant à la castration, le cancer de la prostate résistant à la castration métastatique, le cancer de la prostate résistant à la castration métastatique insensible à une chimiothérapie, le cancer de la prostate sensible aux hormones à rechute biochimique, ou le cancer de la prostate résistant à la castration non-métastatique à haut risque. Dans un aspect, ces formulations comprennent une dispersion solide d'ARN-509 et HPMCAS. Dans un aspect, la dispersion solide d'ARN-509 et HPMCAS peut être obtenue, est obtenue en particulier par extrusion par fusion d'un mélange comprenant ARN-509 et HPMCAS et, éventuellement, par broyage ultérieur dudit mélange extrudé par fusion. Dans un aspect, la dispersion solide d'ARN-509 et HPMCAS peut être obtenue est obtenue en particulier, par séchage par pulvérisation d'un mélange comprenant ARN-509 et HPMCAS dans un solvant approprié.
MA41107A 2014-12-05 2015-12-03 Compositions anti-cancéreuses MA41107B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05
PCT/US2015/063661 WO2016090098A1 (fr) 2014-12-05 2015-12-03 Compositions anti-cancéreuses
EP15817641.2A EP3226841B1 (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses

Publications (2)

Publication Number Publication Date
MA41107A MA41107A (fr) 2017-10-10
MA41107B1 true MA41107B1 (fr) 2025-01-31

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41107A MA41107B1 (fr) 2014-12-05 2015-12-03 Compositions anti-cancéreuses

Country Status (29)

Country Link
US (3) US20170360754A1 (fr)
EP (2) EP4494636A3 (fr)
JP (2) JP6937692B2 (fr)
KR (2) KR102348320B1 (fr)
CN (2) CN114886852A (fr)
AR (1) AR102926A1 (fr)
AU (3) AU2015358490B2 (fr)
BR (1) BR112017011788A2 (fr)
CA (1) CA2969656A1 (fr)
CL (1) CL2017001371A1 (fr)
CO (1) CO2017005572A2 (fr)
CR (1) CR20170216A (fr)
EA (1) EA201791222A1 (fr)
ES (1) ES2996833T3 (fr)
HR (1) HRP20241719T1 (fr)
HU (1) HUE069689T2 (fr)
IL (2) IL252323B (fr)
MA (1) MA41107B1 (fr)
MD (1) MD3226841T2 (fr)
MX (2) MX387933B (fr)
NZ (1) NZ770528A (fr)
PH (1) PH12017500964A1 (fr)
PL (1) PL3226841T3 (fr)
RS (1) RS66323B1 (fr)
SG (1) SG11201704267VA (fr)
SM (1) SMT202400518T1 (fr)
TW (2) TWI754258B (fr)
UA (1) UA120950C2 (fr)
WO (1) WO2016090098A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013323861C1 (en) 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
PL3226841T3 (pl) * 2014-12-05 2025-03-03 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
WO2020144650A1 (fr) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgènes pour le traitement du cancer de la prostate
AU2020215176B2 (en) 2019-01-30 2025-02-27 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
AU2020215177A1 (en) 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2020239478A1 (fr) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques
EP3811932A1 (fr) 2019-10-22 2021-04-28 Zentiva K.S. Forme posologique d'apalutamide
CA3160121A1 (fr) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Inhibiteurs du recepteur des androgenes pour le traitement du cancer de la prostate non metastatique resistant a la castration chez des sujets presentant une deficience hepatique grave
WO2021245285A1 (fr) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (fr) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Méthodes de traitement du cancer de la prostate
WO2023122842A1 (fr) * 2021-12-31 2023-07-06 Gador Limitada Procédé de préparation d'apalutamide, intermédiaires de synthèse et dispersion solide amorphe le contenant
WO2023152611A1 (fr) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide et relugolix pour le traitement du cancer de la prostate
WO2023209555A1 (fr) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate
CN116183787A (zh) * 2022-12-26 2023-05-30 郑州德迈药业有限公司 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
AU2024236119A1 (en) 2023-03-16 2025-09-25 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer
WO2025153768A1 (fr) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition contenant de l'apalutamide nanométrique cristallin
WO2025174375A1 (fr) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020097A1 (fr) 1992-03-31 1993-10-14 British Technology Group Ltd. Steroïdes substitues-17 utiles pour le traitement du cancer
EP0901786B1 (fr) 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
AU2001232348A1 (en) 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
EP1368001B1 (fr) 2001-02-27 2005-10-26 AstraZeneca AB Preparation pharmaceutique comprenant du bicalutamide
EE200300476A (et) 2001-04-02 2003-12-15 Astrazeneca Ab 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
ATE480226T1 (de) * 2001-06-22 2010-09-15 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
CA2474958A1 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen de buses de projection
WO2003077827A1 (fr) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Procede de production de medicament solide en dispersion
AU2003292509B2 (en) 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
GB0502790D0 (en) 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
KR101782236B1 (ko) 2005-05-13 2017-09-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
SI2656841T1 (sl) * 2006-03-27 2016-11-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljanje raka prostate in bolezni, povezanih z androgenimi receptorji
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
LT3124481T (lt) 2010-02-16 2018-06-11 Aragon Pharmaceuticals, Inc. Androgeno receptorių moduliatoriai ir jų panaudojimas
CN102525876B (zh) 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
EP2721003B1 (fr) 2011-06-15 2018-01-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Modulateurs de récepteurs nucléaires et leur utilisation pour le traitement et la prévention d'un cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Inhibiteur de mtor anticancéreux et combinaison anti-androgène
PL3533792T3 (pl) * 2012-06-07 2021-11-29 Aragon Pharmaceuticals, Inc. Postacie krystaliczne modulatora receptora androgenowego
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
BR112015002055A2 (pt) * 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
AU2013323861C1 (en) * 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
HK1211217A1 (en) 2013-01-22 2016-05-20 霍夫曼-拉罗奇有限公司 Pharmaceutical composition with improved bioavailability
KR102121404B1 (ko) 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
WO2014167428A2 (fr) 2013-04-10 2014-10-16 Shilpa Medicare Limited 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe
US9808472B2 (en) * 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015116696A1 (fr) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Thérapies de combinaison et procédés d'utilisation associés pour le traitement du cancer
EA037895B1 (ru) * 2014-02-05 2021-06-02 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
KR102348325B1 (ko) 2014-12-05 2022-01-06 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
PL3226841T3 (pl) 2014-12-05 2025-03-03 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
UA124154C2 (uk) 2016-06-03 2021-07-28 Арагон Фармасьютікалз, Інк. Протиракові композиції
KR20210023987A (ko) 2018-06-20 2021-03-04 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. Arn-509의 결정형, 그 제조방법 및 그 용도
EP3811932A1 (fr) 2019-10-22 2021-04-28 Zentiva K.S. Forme posologique d'apalutamide

Also Published As

Publication number Publication date
CN114886852A (zh) 2022-08-12
EA201791222A1 (ru) 2017-09-29
MA41107A (fr) 2017-10-10
TW201630592A (zh) 2016-09-01
CN106999431A (zh) 2017-08-01
TWI702966B (zh) 2020-09-01
US20170360754A1 (en) 2017-12-21
HRP20241719T1 (hr) 2025-02-14
JP2020143069A (ja) 2020-09-10
US12303493B2 (en) 2025-05-20
CN106999431B (zh) 2022-03-04
NZ731963A (en) 2024-03-22
CO2017005572A2 (es) 2017-09-20
JP6937692B2 (ja) 2021-09-22
KR102348320B1 (ko) 2022-01-10
SG11201704267VA (en) 2017-06-29
ES2996833T3 (en) 2025-02-13
IL279833B (en) 2022-03-01
AR102926A1 (es) 2017-04-05
IL252323A0 (en) 2017-07-31
TW202031248A (zh) 2020-09-01
MX387933B (es) 2025-03-19
EP3226841C0 (fr) 2024-10-09
TWI754258B (zh) 2022-02-01
RS66323B1 (sr) 2025-01-31
EP4494636A2 (fr) 2025-01-22
EP3226841A1 (fr) 2017-10-11
AU2015358490B2 (en) 2021-04-08
KR20200141533A (ko) 2020-12-18
MX2017007203A (es) 2017-08-28
IL279833A (en) 2021-01-31
EP3226841B1 (fr) 2024-10-09
SMT202400518T1 (it) 2025-01-14
JP2017536398A (ja) 2017-12-07
MX2021013965A (es) 2022-01-04
AU2021201979B2 (en) 2023-02-02
AU2015358490A1 (en) 2017-06-08
CL2017001371A1 (es) 2018-01-05
CR20170216A (es) 2017-08-30
BR112017011788A2 (pt) 2017-12-26
UA120950C2 (uk) 2020-03-10
MD3226841T2 (ro) 2025-06-30
PH12017500964A1 (en) 2017-10-18
AU2021201979A1 (en) 2021-04-29
JP7174006B2 (ja) 2022-11-17
US20230233529A1 (en) 2023-07-27
IL252323B (en) 2021-04-29
US20240293374A1 (en) 2024-09-05
KR20170086656A (ko) 2017-07-26
NZ770528A (en) 2024-03-22
WO2016090098A1 (fr) 2016-06-09
CA2969656A1 (fr) 2016-06-09
PL3226841T3 (pl) 2025-03-03
EP4494636A3 (fr) 2025-04-30
HUE069689T2 (hu) 2025-04-28
AU2023202710A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
MA41107B1 (fr) Compositions anti-cancéreuses
MA41111B1 (fr) Compositions anticancéreuses
MA41108B1 (fr) Compositions anticancéreuses
EP3356522A4 (fr) Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants
AU2017275396A1 (en) Anticancer compositions
PH12021551629A1 (en) Traceless linkers and protein-conjugates thereof
MY187047A (en) Selective pyy compounds and uses thereof
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
WO2012037411A3 (fr) Modulateurs des récepteurs des oestrogènes et leurs utilisations
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
BR112017028552A2 (pt) partículas e conjugados direcionados e formulações dos mesmos
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
EA201390598A1 (ru) Антагонист мутантного андрогенного рецептора
MA38356A1 (fr) Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques
Ashok et al. PM250 Synthesis and characterization of Atenolol nanoformulation for effective delivery and increased bioavailability in in vitro model of myocardial infarction